Haematology Testing
Minimal Residual Disease MRD Analysis for TALL Test
The Minimal Residual Disease (MRD) Analysis for TALL Test detects remaining leukemia cells after treatment for T-cell Acute Lymphoblastic Leukemia (TALL), helping monitor treatment effectiveness and guide decisions.
General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.
Review status: No completed medical review is recorded for this page.
At a glance
Plan your test
- Sample
- 3 mL (1 mL min.) of first pull Bone Marrow aspirate in 1 Green Top (Sodium Heparin) tube and 4 mL (3 mL min.) of whole blood in 1 Green Top (Sodium Heparin) tube.
- Results
- Confirm with the laboratory before booking.
- Preparation
- Confirm with the laboratory before booking. Provide the date and time of sampling, previous immunophenotype report, and clinical history at the time of registration.
Payment: M-Pesa and card options can be confirmed during booking.
Insurance & government schemes
Is this test covered for you?
We help you verify whether the Minimal Residual Disease MRD Analysis for TALL Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.
Providers & schemes we can help you check
Government & public schemes
Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.
Private insurers & employer schemes
Names shown for identification only — listing does not imply partnership or guarantee of coverage.
Have these ready when we check
- Insurer or scheme name & policy / member number
- A clinician's request / prescription for the test
- Pre-authorisation letter, if your plan requires one
Free coverage check
Ask us to verify your cover
Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.
Start with fit
Is this the right test for you?
The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.
- ✓Monitoring treatment response in T-cell Acute Lymphoblastic Leukemia (TALL)
- ✓Assessing risk of relapse in TALL patients
- ✓Guiding treatment decisions post-remission
- ✓Evaluating effectiveness of therapy for TALL
- ✓Detecting residual leukemia cells after treatment
In plain language
What this test helps you understand
This test employs advanced flow cytometry techniques to measure specific cell surface markers on blood and bone marrow samples. It detects the presence of residual leukemia cells by identifying specific markers associated with TALL. The precision of this analysis allows healthcare providers to monitor remission status and adjust treatment plans accordingly.
Patients diagnosed with T-cell Acute Lymphoblastic Leukemia (TALL) should consider undergoing the MRD Analysis. It is especially recommended for individuals in remission needing monitoring for potential relapse, patients undergoing treatment to evaluate therapy effectiveness, and those with a history of leukemia and specific risk factors for relapse.
The MRD Analysis provides several significant benefits, including early detection of relapse, informed decision-making regarding treatment adjustments, improved patient outcomes through personalized treatment strategies, and increased confidence for both patients and healthcare providers in managing leukemia.
Results from the MRD Analysis will indicate the presence or absence of residual leukemia cells. A lower MRD level is often associated with a better prognosis. Your healthcare provider will guide you through interpreting your results and discussing the next steps in your treatment plan.
Medical review status
Clinical review pending
A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.
Meet the DNA Labs Kenya medical team →A simple process
What happens next?
You do not have to navigate the test alone. We help you move from question to next step.
Speak with us
We check the test and answer your questions before collection.
Give your sample
Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.
Understand your report
A counselor helps you understand the result and the next steps.
Choose your collection
Home collection or a lab visit
We will explain the sample, preparation, and next steps before anything is collected.
Home collection
Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.
Lab or hub visit
Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.
Ask about locations →Read your report
What common result terms mean
Questions people ask
Frequently asked questions
Collaboration
Open for partnership with hospitals, clinics, doctors & researchers
Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.
Hospitals & clinics
Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.
Doctors & specialists
LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.
Research institutions
Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.
Students & academic projects
Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.
Trust & transparency
Sources, standards & how this page is maintained
Standards & references
- ACMG/AMP technical standards for sequence variant interpretation
- ClinGen curation and gene–disease validity frameworks where applicable
- LOINC-coded reporting for interoperable results
- ISO 9001:2015 quality management; ISO 15189 accreditation in progress
Page provenance
- Last updated: September 27, 2026
- Medical review: not yet completed
- Written for patients & clinicians in Kenya; reviewed periodically against current guidance
Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.
Keep exploring
Related tests
Leukocyte Alkaline Phosphatase Score (LAP Score) Test
The Leukocyte Alkaline Phosphatase (LAP) Score test measures enzyme activity in white blood cells to help diagnose certain blood disorders.
Learn more →PAS Periodic Acid Schiff Stain Blood Bone Marrow Test
The PAS Periodic Acid Schiff Stain Blood Bone Marrow Test helps diagnose blood disorders like leukemia by identifying abnormal cells in blood or bone marrow samples.
Learn more →Sudan Black B Stain Blood Bone Marrow Test
The Sudan Black B Stain Blood Bone Marrow Test helps diagnose leukemia by identifying specific cell types in the bone marrow. It is a crucial tool for hematologists.
Learn more →Absolute Lymphocyte Count Test
The Absolute Lymphocyte Count Test measures the number of lymphocytes in your blood, helping to assess immune system health and detect conditions like infections and blood cancers.
Learn more →